Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CORIMUNO-19: Cohort Multiple Randomized Controlled Trials of Immune Modulatory and Other Treatments in Hospitalized COVID-19 Patients
2020-001246-18Phase 2Terminated
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sarilumab, tocilizumab, anakinra, hydroxychloroquine, azithromycin and 4 more in coronavirus disease 2019 (COVID-19) (9 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Primary endpoint (group 1, non-ICU patients). Started Mar 2020; status: terminated.
02
Drugs
sarilumabtocilizumabanakinrahydroxychloroquineazithromycin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001246-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001246-18.